GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Add as a preferred source on Google
MEDFORD, N.Y., Feb. 22, 2018 -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2017 after the close of trading on Thursday, March 8, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by dialing 877-407-0778 from the US or 201-689-8565 from outside the US. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at www.chembio.com. A telephone replay will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 26056 until 4:30pm ET on Thursday, March 15, 2018.
Contact:
Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
[email protected]
